Waqqas Afif
Associate Professor, Department of Medicine, McGill University
MD, M.Sc., FRCPC
Inflammatory Bowel Disease
Dr. Afif, an accomplished clinician, educator, and researcher, brings a wealth of expertise in Inflammatory Bowel Disease (IBD) and Gastroenterology.
Dr. Afif earned his M.D.C.M. from McGill University, followed by residency training in Internal Medicine and Gastroenterology. He further specialized in IBD through a fellowship at the Mayo Clinic (Rochester, MN) and obtained a Master of Science in Epidemiology at McGill. He has been a faculty member at McGill since 2009, progressing to Associate Professor in the Department of Medicine in 2017. His leadership roles include Site Director for Gastroenterology at the Montreal General Hospital, Co-Director of the Multidisciplinary Eosinophilic Esophagitis Clinic, and Director of the Clinical Trials Unit at the McGill IBD Centre.
As an internationally recognized researcher, Dr. Afif has authored over 100 peer-reviewed publications and led numerous clinical trials focusing on optimizing biologic therapies for IBD. His contributions to advancing patient care and education have been recognized through multiple awards, including the Michael Lichter Teacher of the Year Award in 2024. A dedicated mentor, he has played a pivotal role in the training of medical students, residents, and fellows, previously serving as Chair of the Gastroenterology Competence Committee at McGill.
1. Restellini S, Khanna R, Afif W: Therapeutic Drug Monitoring With Ustekinumab and Vedolizumab in Inflammatory Bowel Disease. Inflamm Bowel Dis. 2018 Sep 15;24(10):2165-2172.
2. Nguyen GC, Murthy SK, Bressler B, Lam MCW, Alali A, Toumi A, Reinglas J, Rampersad A, Weizman AV, Afif W; CINERGI group. Quality of care and outcomes among hospitalized inflammatory bowel disease patients: A Multicenter Retrospective Study. Inflamm Bowel Dis. 2017 May;23(5):695-701.
3. Battat R, Kopylov U, Bessissow T, Bitton A, Cohen A, Jain A, Martel M, Seidman E, Afif W. Association between ustekinumab trough concentrations and clinical, biomarker, and endoscopic outcomes in patients With Crohn's disease. Clin Gastroenterol Hepatol. 2017 Sep;15(9):1427-1434.e2.
4. Afif W, Sandborn WJ, Faubion WA, Rahman M, Harmsen SW, Zinsmeister AR, Loftus EV Jr. Risk factors for lymphoma in patients with inflammatory bowel disease: a case-control study. Inflamm Bowel Dis. 2013 Jun;19(7):1384-9.
5. Afif W, Loftus EV Jr, Faubion WA, Kane SV, Bruining DH, Hanson KA, Sandborn WJ.Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol. 2010 May;105(5):1133-9.
RSS